...
机译:Frentuximab Vedotin的第1阶段多中心试验,用于类固醇难治性急性接枝 - 与宿主病
Massachusetts Gen Hosp Blood &
Marrow Transplant Program Boston MA 02114 USA;
Mem Sloan Kettering Canc Ctr Dept Med Adult Bone Marrow Transplant Serv 1275 York Ave New York;
Dana Farber Canc Inst Dept Biostat &
Computat Biol Boston MA 02115 USA;
Massachusetts Gen Hosp Blood &
Marrow Transplant Program Boston MA 02114 USA;
Dana Farber Canc Inst Div Hematol Malignancies Boston MA 02115 USA;
Massachusetts Gen Hosp Blood &
Marrow Transplant Program Boston MA 02114 USA;
Ohio State Univ Blood &
Marrow Transplant Program Columbus OH 43210 USA;
Ohio State Univ Blood &
Marrow Transplant Program Columbus OH 43210 USA;
Massachusetts Gen Hosp Blood &
Marrow Transplant Program Boston MA 02114 USA;
Massachusetts Gen Hosp Blood &
Marrow Transplant Program Boston MA 02114 USA;
Massachusetts Gen Hosp Blood &
Marrow Transplant Program Boston MA 02114 USA;
Dana Farber Canc Inst Div Hematol Malignancies Boston MA 02115 USA;
Dana Farber Canc Inst Div Hematol Malignancies Boston MA 02115 USA;
Dana Farber Canc Inst Div Hematol Malignancies Boston MA 02115 USA;
机译:Frentuximab Vedotin的第1阶段多中心试验,用于类固醇难治性急性接枝 - 与宿主病
机译:None
机译:在复发/难治性霍奇金淋巴瘤自体移植前进行布伦妥昔单抗维多汀二线治疗作为二线治疗的多中心II期试验的结果
机译:抗胸腺细胞球蛋白(ATG-Fresenius)预防无关供体骨髓移植的小儿和成年患者的急性和慢性移植物抗宿主病
机译:急性脊髓损伤情况下的脑脊液转移和鞘内压监测:一项多中心前瞻性随机对照试验。
机译:Brentuximab Vedotin在复发或难治的高表达CD30的非霍奇金淋巴瘤中的功效:多中心开放标签的II期试验结果
机译:在复发/难治性霍奇金淋巴瘤自体移植之前,以布伦妥昔单抗Vedotin为二线治疗的多中心II期临床试验结果